Overview

Obesity is a chronic, recurrent disease caused by multiple factors and may lead to a range of clinical complications, including cardiovascular disease, dyslipidemia, type 2 diabetes mellitus, and hypertension. There are many factors influencing the development of obesity, including genetic, metabolic, behavioral, socio-cultural, and environmental factors. It is crucial to study the pathogenesis of obesity and develop preventive treatments for specific targets. Antibody drugs, which are prepared through cellular and genetic engineering techniques, have better safety and specificity and are a powerful tool for treating obesity and other diseases. Protheragen is at the forefront of anti-obesity research and offers a one-stop anti-obesity antibody therapy development service. We are constantly updating our approach to advancing the development of innovative anti-obesity therapies through a full range of technical support, including gene therapy, antibody therapies, etc.

Matching Different Needs: Customised Solutions for Anti-Obesity Antibody Therapy Development

We develop safe and effective anti-obesity antibodies that selectively target specific factors and minimize off-target effects. Integrated solutions provide comprehensive support at different stages of anti-obesity antibody therapy development. Specific development processes include the following:

Antibody Screening

The first step in the development of an innovative anti-obesity antibody drug against a specific target is to screen the antibody candidate. We have a variety of technologies for antibody screening, including phage display, yeast display, bacterial display, hybridoma technology, etc.

Antibody Optimization

Antibody optimization is a key step in the development of anti-obesity antibodies. We screen and further optimize to obtain antibodies with high affinity, stability, and safety. Antibodies are produced through efficient expression and purification and subsequently validated preclinically. Our researchers establish the best pathway to optimize the molecule to achieve the desired goal.

We develop anti-obesity antibodies against the following specific loci.

• Gastric Inhibitory Polypeptide (GIP) Receptor (GPIR)
  GIP is an enteroglucagon that stimulates insulin secretion by activating GPIR and exerts other passages. Blocking GPIR is a potential means of improving obesity and combating insulin resistance. The use of antibodies specific to GPI or GIPR is an attractive strategy to eliminate GIPR signaling. We develop monoclonal antibodies against GIP or GIPR antagonist antibodies and evaluate their effects on body weight, food intake, and metabolism in obese models.
• Fibroblast Growth Factor (FGF)
  Expressed in the pancreas, adipose tissue, and liver, FGF21 is essential for energy homeostasis, glucose, and lipids, and is considered a candidate for the treatment of obesity, and metabolic diseases. Natural FGF21 has a short half-life and its therapeutic potential is somewhat limited. We develop various long-acting FGF21-based antibodies, such as combining p-FGF21 with Fc fragments to extend the half-life. They play a role in the treatment of obesity and other metabolic problems by mimicking the effect of FGF21.
• Others
  In addition, we are happy to develop specific antibodies against other targets, such as neurotensin (NTS), and evaluate their affinity, in vitro and in vivo anti-obesity activity, etc.

Preclinical Studies

After identifying the molecular form of the antibody and expressing the antibody molecule, it needs to be functionally validated, evaluated for durability, and evaluated in animal models.

• Obesity Models
  We offer a variety of obesity models to study obesity mechanisms and the potential of anti-obesity antibodies for targeted therapy. These models include In Vitro Models including adipose tissue, 3T3-L1 Cells, etc., and In Vivo Models such as Mice and Rats. All models are validated to meet various assay needs.
• Evaluation of antibody therapy
  Preclinical studies for anti-obesity antibody therapies include pharmacodynamic studies, pharmacokinetic studies, and safety assessments. We measure the biological activity of anti-obesity antibodies through cell-based functional analyses, including gene expression analysis, glucose uptake assays, etc. The binding affinity of these antibodies to their targets is tested and the changes in glucose tolerance, body weight, etc., in obesity models after antibody treatment are also analyzed.

Pharmacodynamics Study	Food/Water Intake Assessment Quantitative Analysis of Body Fat Distribution Energy Expenditure Monitoring Measurement of Ectopic Fat Accumulation Molecular Biomarker Analysis
Pharmacokinetics Study	DMPK Study of Anti-Obesity Drugs ADME Study of Anti-Obesity Drugs
Bioanalysis	Biological Analysis of Macromolecular Drugs Bioanalysis of Small Molecule Drugs
Safety Assessment	Safety Pharmacology Studies Toxicology Studies

Workflow

Applications

• Antibody drug development offers new safe and efficient strategies for obesity intervention and treatment.
• The development of anti-obesity antibody drugs targeting specific targets also provides ideas for metabolic disease treatment research.
• Anti-obesity antibody drugs targeting specific targets may also have potential applications in the treatment of cancer.

Advantages

• We engage in in-depth discussions with our clients to customize anti-obesity antibody therapeutics by combining years of practical experience with advanced technologies.
• We offer a one-stop service for the development of anti-obesity antibody therapeutics, including antibody screening, antibody optimization, and preclinical research services (pharmacodynamic studies, pharmacokinetic evaluations, safety evaluations, etc.).
• We have optimized the entire process of antibody preparation and have the capability to produce antibodies on a large scale.

Other Cutting-edge Services for Obesity Research

Our senior research team is always at the forefront of obesity research, focusing on creating flexible and innovative solutions according to the different research needs of our clients. Our services include not only the development and preclinical evaluation of anti-obesity therapies but also comprehensive assessment of obesity risk, high-precision diagnostic testing services, obesity prediction, and gene editing. In addition to this, we also analyze obesity-related biomarkers and explore the microbiome and pathology of the samples. We also tailor unique weight loss and weight management programs.

Publication Data

Frequently Asked Questions

What is the role of phage display technology in antibody screening?

Phage display technology is a method for screening antibodies in vitro. A gene encoding a polypeptide or protein is inserted into the appropriate position of the phage shell protein structure gene, causing it to express the fusion protein. With the reassembly of the daughter phage the fusion protein is then presented on the surface of the phage. These phage expressing the fusion protein is used for multiple rounds of screening for antibodies that can bind to the target antigen and are expanded in Escherichia coli. Repeated screening increases the proportion of phages that specifically recognize the target, ultimately yielding the target peptide or protein.

Will I be updated on the progress of my anti-obesity antibody therapeutics project?

Of course, we have an efficient project management system and will keep you updated on the progress of your anti-obesity antibody development and preclinical research projects. In addition to regular progress updates, we also communicate with our clients on specific nodes and matters that need to be discussed.

Protheragen has extensive experience in the study of antibody drugs for obesity treatment and offers a one-stop service from antibody development to preclinical analysis. Our goal is to discover novel antibodies with high specificity and affinity, avoiding toxicity and off-target binding, and contributing to innovative research in anti-obesity therapies. Please feel free to contact us to discuss the detailed experimental process if you are interested in this area.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Anti-Obesity Cell Therapy Development
• Anti-Obesity Gene Therapy Development
• Anti-Obesity Nanotherapy Development
• Anti-Obesity Small Molecule Drug Development
• Anti-Obesity Tissue Engineering Therapy Development